GlaxoSmithKline has been actively recruiting a slate of new execs for the company as Emma Walmsley settles into her new job as CEO.
The latest pick up: Tony Wood, Pfizer’s senior vice president of medicinal sciences, has been wooed over to take a key R&D posting at the UK pharma giant. And the move includes a shift in assignments tied to a new effort at GSK involving the use of artificial intelligence in drug development.
The news, first reported by FierceBiotech, was confirmed to me this morning.
Tony Wood has been appointed Senior Vice President, Platform Technology and Science, Pharma R&D at GSK and will assume his position in October. In this role he will be responsible for delivering the critical end-to-end scientific and technical platform that supports the discovery and development of our medicines. This appointment reflects our ongoing commitment to the successful delivery of our deep mid-stage pipeline and enhancing our R&D capabilities, particularly in areas such as computational sciences.
The spokesperson adds that John Baldoni, who previously led this effort, is moving to head up a new team focused on “enhancing drug discovery through the use of in silico technology — including artificial intelligence, machine learning and deep learning.”
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 17,000+ biopharma pros who read Endpoints News by email every day.Free Subscription